What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs
| Autor: | Datta, S.S., Sharma, V., Mukherjee, A., Agrawal, S., Sirohi, B., Gyawali, B. |
|---|---|
| Zdroj: | In ESMO Open November 2024 9(11) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|